Boston University Chobanian & Avedisian School of Medicine

Supplemental training

A Patient-Centered Approach to Opioid Tapering


CME information


  Create an account or log in to participate in this activity

Release Date: April 1, 2018
Date of Most Recent Review: August 1, 2024
Expiration Date: July 31, 2025

Accreditation

Jointly Accredited Provider with Commendation | Interprofessional Continuing Education

In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Contact Hours: .5, of which .5 are eligible for pharmacology credit.

Participants will receive credit after watching the entire presentation, completing the post-test with a passing grade (70% or greater), and completing an evaluation. Participants may retake the post-test until a passing score is achieved.

Risk Management

This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study.

Opioid Education

This program meets the criteria of the Massachusetts Board of Registration in Medicine for opioid education.


Content Development

Content for this module was developed in collaboration with Granite Health, Concord, New Hampshire.


Needs Statement

Primary care providers and others who prescribe opioids for chronic pain struggle with when and how best to taper patients who are on high doses of opioids in a patient-centered and medically-sound way, while keeping their patients safe and managing their pain. This one-hour program will share best practices in opioid tapering. Identifying when to taper and knowing how to do so will result in improved patient care and reduce the risk of harm associated with high doses of opioids.


Objectives

At the conclusion of this activity, participants will be better able to assess when and how to taper opioid doses to safely and appropriately manage chronic pain.


Target Audience

Primary and specialty clinicians, nurse practitioners, physician assistants, and nurses involved in the management of patients with chronic pain.


Disclosure Policy

Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.

Faculty

Daniel Alford, MD, MPH (Course Director)
Professor of Medicine
Director, Clinical Addiction Research and Education (CARE) Unit
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center

P. Travis Harker, MD (Content Development)
Chief Medical Officer
Appledore Medical Group
Portsmouth, NH

Seddon Savage, MD, MS, FASAM (Content Development)
Adjunct Associate Professor of Anesthesiology
Geisel School of Medicine
Dartmouth Medical School

Faculty members have no relevant financial relationships to disclose.
This presentation does include discussion of the off-label use of clonidine and tizanidine to treat opioid withdrawal symptoms. Clonidine and tizanidine are not FDA approved for this use.

Planners: Colleen Labelle BSN RN-BC CARN, Nursing Course Advisor; Carmela Townsend DNP, MS/MBA, RN, Lead Nurse Planner; and Ilana Hardesty, Chobanian & Avedisian School of Medicine CCE Program Manager, have no relevant commercial relationships to disclose.


Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

Boston University Federation of State Medican Boards